Use of metformin in patients with sickle cell disease

Han, Jin; Saraf, Santosh L.; Molokie, Robert E.

doi:10.1002/ajh.25313

Cited by 4 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase in HbF was shown to be minimal in patients with SS, Sβ 0 genotype [130]. Although some concerns on the use of metformin in SCD patients was raised due to the possible lactic acidosis which might accelerate HbS polymerization, no data on lactic acidosis were reported in patients with SCD [130]. Although the data on metformin are stimulating, the small number of SCD patients and the absence of data on clinical outcomes limit the conclusion of its use as a HbF inducer in clinical practice [131].…”

Section: Metforminmentioning

confidence: 90%

“…It is noteworthy that the combination of metformin and HU have a synergic effect on the reduction in the percentage of sickled erythroid cells compared with monotherapy. Metformin was also evaluated in 18 patients with SCD with SS, Sβ 0 , Sβ + and SC genotypes [130]. The increase in HbF was shown to be minimal in patients with SS, Sβ 0 genotype [130].…”

Section: Metforminmentioning

confidence: 99%

“…Metformin was also evaluated in 18 patients with SCD with SS, Sβ 0 , Sβ + and SC genotypes [130]. The increase in HbF was shown to be minimal in patients with SS, Sβ 0 genotype [130]. Although some concerns on the use of metformin in SCD patients was raised due to the possible lactic acidosis which might accelerate HbS polymerization, no data on lactic acidosis were reported in patients with SCD [130].…”

Section: Metforminmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective

et al. 2022

View full text Add to dashboard Cite

A significant amount of attention has recently been devoted to the mechanisms involved in hemoglobin (Hb) switching, as it has previously been established that the induction of fetal hemoglobin (HbF) production in significant amounts can reduce the severity of the clinical course in diseases such as β-thalassemia and sickle cell disease (SCD). While the induction of HbF using lentiviral and genome-editing strategies has been made possible, they present limitations. Meanwhile, progress in the use of pharmacologic agents for HbF induction and the identification of novel HbF-inducing strategies has been made possible as a result of a better understanding of γ-globin regulation. In this review, we will provide an update on all current pharmacological inducer agents of HbF in β-thalassemia and SCD in addition to the ongoing research into other novel, and potentially therapeutic, HbF-inducing agents.

show abstract

Section: Metforminmentioning

confidence: 90%

Section: Metforminmentioning

confidence: 99%

Section: Metforminmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective

et al. 2022

View full text Add to dashboard Cite

show abstract

“…29,30 However, these findings are based on laboratory experiments with no clinical data. Two recent retrospective studies reported in vivo evidence of an increase in HbF level in response to metformin use in patients with SCD (N 5 18) 31 and those without SCD (N 5 7), 32 although neither reported statistically significant findings. Both studies were limited to a small number of patients, and neither examined the relationship between metformin use and SCD-related outcomes or health care utilization.…”

Section: Introductionmentioning

confidence: 98%

“…Both studies were limited to a small number of patients, and neither examined the relationship between metformin use and SCD-related outcomes or health care utilization. 31,32 Therefore, the relation of metformin utilization to clinical outcomes and health care utilization in adults with SCD and DM, to date, has not been studied.…”

Section: Introductionmentioning

confidence: 99%